| Literature DB >> 28351216 |
Arlene C Neuman1, Susan B Waltzman1, William H Shapiro1, Jonathan D Neukam1, Annette M Zeman1, Mario A Svirsky1.
Abstract
Ninety-four unilateral CI patients with bimodal listening experience (CI plus HA in contralateral ear) completed a questionnaire that focused on attitudes toward hearing aid use postimplantation, patterns of usage, and perceived bimodal benefits in daily life. Eighty participants continued HA use and 14 discontinued HA use at the time of the questionnaire. Participant responses provided useful information for counseling patients both before and after implantation. The majority of continuing bimodal (CI plus HA) participants reported adapting to using both devices within 3 months and also reported that they heard better bimodally in quiet, noisy, and reverberant conditions. They also perceived benefits including improved sound quality, better music enjoyment, and sometimes a perceived sense of acoustic balance. Those who discontinued HA use found either that using the HA did not provide additional benefit over the CI alone or that using the HA degraded the signal from the CI. Because there was considerable overlap in the audiograms and in speech recognition performance in the unimplanted ear between the two groups, we recommend that unilateral CI recipients are counseled to continue to use the HA in the contralateral ear postimplantation in order to determine whether or not they receive functional or perceived benefit from using both devices together.Entities:
Keywords: bimodal benefit; bimodal hearing; cochlear implant; hearing aid
Mesh:
Year: 2017 PMID: 28351216 PMCID: PMC5435367 DOI: 10.1177/2331216517699530
Source DB: PubMed Journal: Trends Hear ISSN: 2331-2165 Impact factor: 3.293
Demographic Information for 80 Participants Who Continued HA Use and 14 Participants Who Discontinued HA Use.
| Continue HA use ( | Discontinued HA use ( | |
|---|---|---|
| Age (years): | 64.5 (16.3) | 64.8 (12.9) |
| Gender ( | 29 M, 51 F | 7 M, 7 F |
| Hearing loss (years): | 32.7 (16.3) | 33.6 (19.6) |
| HA use (years): | 23.3 (15.3) | 27.0 (20.4) |
| CI use (years): Mdn (range) | 1.3 (.21–12.8) | 2.9 (0.89–11.9) |
| Mdn LF PTA HA ear (250 and 500 Hz) | 61.25 dB HL (unaided) 40.0 dB HL (aided) | 73.8 dB HL (unaided) 43.75 dB HL*(aided) |
| Mdn PTA HA ear (500, 1000, and 2000 Hz) | 81.67 dB HL (unaided) 44.17 dB HL (aided) | 92.2 dB HL (unaided) 48.33 dB HL[ |
| Etiology (N) | Etiology (N) | |
| Unknown | 32 | 4 |
| Noise induced | 10 | 2 |
| Meniere’s | 6 | 1 |
| Otosclerosis | 9 | 0 |
| Ototoxicity | 2 | 1 |
| Trauma | 2 | 0 |
| Genetic | 5 | 4 |
| Other | 14 | 2 |
| Ear implanted | 50 right, 30 left | 4 right, 5 left, 5 bilateral |
Note. HA = hearing aid; M = mean, SD = standard deviation; Mdn = median; N = number; M = male; F = female; LF PTA = low-frequency pure tone average; PTA = pure tone average.
Data Available for only 10 of the 14 Discontinued HA users.
CI Devices (Implant Type, Processor, and Strategy) Used by Participants.
| Continue HA use ( | Discontinued HA use ( | |||||||
|---|---|---|---|---|---|---|---|---|
| Processor |
| Strategy |
| Processor |
| Strategy |
| |
| Cochlear | Freedom | 6 | ACE | 54 | Freedom | 2 | ACE | 10 |
| N5 | 34 | N5 | 5 | |||||
| N6 | 14 | N6 | 3 | |||||
| Advanced bionics | Naida Q70 | 11 | CIS | 1 | Naida Q70 | 2 | Optima S | 2 |
| Optima S | 8 | Harmony | 2 | S-Fidelity 120 | 2 | |||
| Optima P | 2 | |||||||
| Harmony | 10 | P-Fidelity 120 | 5 | |||||
| S-Fidelity | 5 | |||||||
| Med-El | Sonnet | 1 | FS4 | 1 | ||||
| Opus 2 | 4 | FSP | 3 | |||||
| FS4-P | 1 | |||||||
Note. CI = cochlear implant; HA = hearing aid; N = number.
Hearing Aids (Manufacturer) and Type of HAs Used by Continuing HA Users.
| N | |
|---|---|
| HA manufacturer | |
| Audibel | 1 |
| Hansaton | 1 |
| Miracle ear | 2 |
| Oticon | 15 |
| Phonak | 37 |
| Resound | 6 |
| Siemens | 3 |
| Starkey | 5 |
| Telex | 1 |
| Unitron | 1 |
| Widex | 8 |
| HA styles | |
| Behind the ear | 55 |
| Receiver in canal | 19 |
| In the ear | 5 |
| Completely in canal | 1 |
Note. HA = hearing aid; N = number.
Figure 1.(a) Pure tone audiograms of the unimplanted ear of 80 bimodal patients who continue to use a hearing aid. (b) Pure tone audiograms of the unimplanted ear of 14 patients who discontinued hearing aid use after a period of bimodal experience.
Figure 2.Top panel: Comparison of CNC (consonant-nucleus-consonant) word scores for individual bimodal users tested using the HA alone and the CI alone. The diagonal line represents equivalent performance. The dashed lines represent the upper and lower 95% confidence interval for a single list comparison. Filled circles represent data of continuing hearing aid users. Open triangles represent users who discontinued HA use. Middle panel: Comparison of CNC (consonant-nucleus-consonant) word scores for individual bimodal users tested using the CI alone and the CI + HA. Bottom panel: Comparison of the best unimodal (either CI alone or HA alone) condition score and the bimodal (CI + HA) condition score for individual users on CNC (consonant-nucleus-consonant) words.
Figure 3.Top panel: Comparison of AZBio sentence scores for individual continuing HA users tested using the HA alone and the CI alone. The diagonal line represents equivalent performance. The dashed lines represent the upper and lower 95% confidence interval for a single list comparison. Middle panel: Comparison of AZBio sentence scores for individual continuing HA users tested using the CI alone and the CI + HA. Bottom panel: Comparison of AZBio sentence scores for individual continuing HA users in the best unimodal (either CI alone or HA alone) condition and the bimodal (CI + HA) condition.
Device Preference of Continuing HA Users as a Function of Environment or Signal.
| CI | HA | CI + HA | No preference | Total | |
|---|---|---|---|---|---|
| Quiet | 4% | 2.5% | 91% | 2.5% | 80 |
| Noise | 5% | 3% | 79% | 14% | 79 |
| Reverberation | 3% | 7% | 69% | 21% | 72 |
| Music | 1% | 15% | 68% | 16% | 75 |
Note. CI = cochlear implant; HA = hearing aid; N = number of reponses. Numbers represent the percentage of participants indicating choice of device(s) judged to yield better hearing.